| 赵 球,何光照,肖 敏.血清RASSF1A甲基化评估PD-1单抗治疗非小细胞肺癌疗效的临床价值[J].肿瘤学杂志,2021,27(5):369-373. |
| 血清RASSF1A甲基化评估PD-1单抗治疗非小细胞肺癌疗效的临床价值 |
| Clinical Value of Serum RASSF1A Methylation in Evaluating Efficacy of Anti-PD-1 Therapy for Non-small-cell Lung Cancer |
| 投稿时间：2020-12-29 |
| DOI：10.11735/j.issn.1671-170X.2021.05.B008 |
|
 |
| 中文关键词: 非小细胞肺癌 RASSF1A 甲基化 程序性细胞死亡蛋白1 |
| 英文关键词:non-small-cell lung cancer RASSF1A methylation programmed cell death |
| 基金项目:常州市卫生计生委重大科技项目(ZD201611) |
|
| 摘要点击次数: 872 |
| 全文下载次数: 250 |
| 中文摘要: |
| 摘 要：［目的］ 评价RASSF1A基因甲基化水平变化评估程序性细胞死亡蛋白1(programmed cell death，，PD-1)单抗治疗晚期转移性非小细胞肺癌（non-small cell lung cancer，NSCLC）疗效以及预后中的价值。［方法］ 研究纳入70例Ⅳ期NSCLC患者，在PD-1单抗治疗前（基线）、每次影像学评估疗效的时间点收集血清标本检测RASSF1A基因甲基化，RASSF1A基因甲基化水平和临床反应之间的关系分析使用非参数Wilcoxon符号秩检验。所有患者均通过影像学评估及电话随访获得无进展生存时间（progression-free survival，PFS），采用Kaplan-Meier和Log-rank检验绘制生存曲线。［结果］ 在治疗有效亚组中，血清RASSF1A基因甲基化水平与基线相比明显下降 (P<0.01)，相反，在治疗无效亚组中，血清RASSF1A基因甲基化水平与基线相比明显上升 (P<0.01)。血清RASSF1A基因甲基化水平降低与NSCLC患者具有较好的PFS相关(P=0.0072)。 ［结论］ 血清RASSF1A基因甲基化水平可以用来预测PD-1单抗治疗的晚期NSCLC的临床疗效。 |
| 英文摘要: |
| Abstract：［Objective］ To analyze the value of serum RASSF1A methylation status in evaluating the efficacy of anti-PD-1 therapy for non-small-cell lung cancer(NSCLC) and the prognosis of patients. ［Methods］ Seventy patients with stage Ⅳ NSCLC were treated with anti-PD-1 mAbs. The efficacy of treatment was evaluated by imaging findings，the progression-free survival(PFS) of patients was analyzed with Kaplan-Meier curve. Serum RASSF1A methylation levels were detcected，the association between RASSF1A methylation levels and clinical response was analyzed using the nonparametric Wilcoxon matched-pairs ranked tests. The progression-free survival time were obtained by imaging evaluation and telephone follow-up of all the patients. Kaplan-Meier and the Log-rank test were used to plot the survival curve. ［Results］ In responding patients，serum RASSF1A methylation levels significantly decreased compared with baseline levels(P<0.01)，while in non-responders，serum RASSF1A methylation levels significantly increased（P<0.01). The decreased RASSF1A methylation levels were associated with longer PFD in metastatic NSCLC patients(P=0.0072). ［Conclusion］ The detection of serum RASSF1A methylation level may be used to monitor and predict clinical efficacy of anti-PD-1 in NSCLC patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |